Indacaterol: a comprehensive review

References

• HananiaNAMarciniukDDA unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European SocietyChest2011140356556621896511
   PubMed Web of Science ®Google Scholar
• AnthonisenNRConnettJEMurrayRPSmoking and lung function of Lung Health Study participants after 11 yearsAm J Respir Crit Care Med2002166567567912204864
   PubMed Web of Science ®Google Scholar
• MaltaisFDennisNChanCKRationale for earlier treatment in COPD: a systematic review of published literature in mild-to-moderate COPDCOPD20131017910323272663
   PubMedGoogle Scholar
• LacasseYGoldsteinRLassersonTJMartinSPulmonary rehabilitation for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20064CD00379317054186
   PubMedGoogle Scholar
• EganCDeeringBMBlakeCShort term and long term effects of pulmonary rehabilitation on physical activity in COPDRespir Med2012106121671167923063203
   PubMed Web of Science ®Google Scholar
• National Emphysema Treatment Trial Research GroupPatients at high risk of death after lung-volume-reduction surgeryN Engl J Med2001345151075108311596586
   PubMed Web of Science ®Google Scholar
• SciurbaFCErnstAHerthFJA randomized study of endobronchial valves for advanced emphysemaN Engl J Med2010363131233124420860505
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline CentreChronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary careLondon, UKNational Clinical Guideline Centre Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/EnglishAccessed April 12, 2013
   Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease Revised 2011. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdfAccessed April 12, 2013
   Google Scholar
• Van der PalenJMonninkhofEvan der ValkPVisserAManaging COPD: no more nihilism!Patient Educ Couns200452322122314998589
   PubMed Web of Science ®Google Scholar
• CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
   PubMed Web of Science ®Google Scholar
• SiafakasNMVermeirePPrideNBOptimal assessment and management of chronic obstructive pulmonary disease (COPD)Eur Respir J199588139814207489808
   PubMed Web of Science ®Google Scholar
• ATS StatementStandards for the diagnosis and care of patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20051525S78S121
   Google Scholar
• StämpfliMRAndersonGPHow cigarette smoke skews immune responses to promote infection, lung disease and cancerNat Rev Immunol20099537738419330016
   PubMed Web of Science ®Google Scholar
• HoggJCMacklemPTThurlbeckWMSite and nature of airway obstruction in chronic obstructive lung diseaseN Engl J Med196827825135513605650164
   PubMed Web of Science ®Google Scholar
• CosioMGhezzoHHoggJCThe relations between structural changes in small airways and pulmonary-function testsN Engl J Med19782982312771281651978
   PubMed Web of Science ®Google Scholar
• HoggJCChuFUtokaparchSThe nature of small-airway obstruction in chronic obstructive pulmonary diseaseN Engl J Med2004350262645265315215480
   PubMed Web of Science ®Google Scholar
• McDonoughJEYuanRSuzukiMSmall-airway obstruction and emphysema in chronic obstructive pulmonary diseaseN Engl J Med2011365171567157522029978
   PubMed Web of Science ®Google Scholar
• KraftMAsthma and chronic obstructive pulmonary disease exhibit common origins in any country!Am J Respir Crit Care Med2006174323824416864716
   PubMed Web of Science ®Google Scholar
• FabbriLMRomagnoliMCorbettaLDifferences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2003167341842412426229
   PubMed Web of Science ®Google Scholar
• BarnesPJAgainst the Dutch hypothesis: asthma and chronic obstructive pulmonary disease are distinct diseasesAm J Respir Crit Care Med2006174324024316864717
   PubMed Web of Science ®Google Scholar
• Pocket Guide for Asthma Management and PreventionA pocket guide for physician and nurses Updated 2011Global Initiative for Asthma2011 Available from: http://www.ginasthma.org/Accessed April 12, 2013
   Google Scholar
• RossiAKhiraniSCazzolaMLong-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safetyInt J Chron Obstruct Pulmon Dis2008341918488425
   PubMedGoogle Scholar
• TashkinDPFabbriLMLong-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agentsRespir Res201011114921034447
   PubMed Web of Science ®Google Scholar
• RodrigoGJNanniniLJTiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysisPulm Pharmacol Ther200720549550216621638
   PubMed Web of Science ®Google Scholar
• SethiSCoteCBronchodilator combination therapy for the treatment of chronic obstructive pulmonary diseaseCurr Clin Pharmacol201161486121235463
   PubMedGoogle Scholar
• MahlerDAD’UrzoABatemanEDConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomized, double-blind comparisonThorax201267978178822544891
   PubMed Web of Science ®Google Scholar
• van NoordJABuhlRLaForceCQVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax201065121086109120978028
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBTORCH InvestigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• QaseemAWiltTJWeibergerSEDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the ACP, ACCP, ATS and ERSAnn Intern Med2011155317919121810710
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoAEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• RibeiroMChapmanKRComparative efficacy of indacaterol in chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20127314515222419862
   PubMed Web of Science ®Google Scholar
• SaettaMGhezzoHKimWDLoss of alveolar attachments in smokers. A morphometric correlate of lung function impairmentAm Rev Respir Dis198513248949004051324
   PubMed Web of Science ®Google Scholar
• CooperCBThe connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and functionAm J Med200611910S1213117113394
   PubMed Web of Science ®Google Scholar
• FletcherCPetoRTinkerCThe Natural History of Chronic Bronchitis and Emphysema An Eight-Year Study of Early Chronic Obstructive Lung Disease in Working Men in LondonOxford, UKOxford University Press1976
   Google Scholar
• MacklemPTTherapeutic implications of the pathophysiology of COPDEur Respir J201035367668020190332
   PubMed Web of Science ®Google Scholar
• Dal VecchioLPoleseGPoggiRRossiA“Intrinsic” positive end-expiratory pressure in stable patients with chronic obstructive pulmonary diseaseEur Respir J19903174802178961
   PubMed Web of Science ®Google Scholar
• KhiraniSPoleseGAlivertiAOn-line monitoring of lung mechanics during spontaneous breathing: a physiologic studyRespir Med2010104346347120096552
   PubMed Web of Science ®Google Scholar
• O’ DonnellDEParkerCMCOPD exacerbations – 3: pathophysiologyThorax200661435436116565268
   PubMed Web of Science ®Google Scholar
• RossiAKhiraniSPEEPi and the air-bag effectRespiration200977325625819346761
   PubMed Web of Science ®Google Scholar
• O’DonnellDERevillSMWebbKADynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001164577077711549531
   PubMed Web of Science ®Google Scholar
• OfirDLavenezianaPWebbKALamYMO’DonnellDEMechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2008177662262918006885
   PubMed Web of Science ®Google Scholar
• CalverleyPMKoulourisNGFlow limitation and dynamic hyperinflation: key concepts in modern respiratory physiologyEur Respir J200525118619915640341
   PubMed Web of Science ®Google Scholar
• TzaniPAielloMEliaDDynamic hyperinflation is associated with a poor cardiovascular response to exercise in COPD patientsRespir Res20111215022074289
   PubMed Web of Science ®Google Scholar
• DiazOVillafrancaCGhezzoHRole of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at restEur Respir J200016226927510968502
   PubMed Web of Science ®Google Scholar
• TantucciCDuguetASimilowskiTZelterMDerenneJPMilic-EmiliJEffect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary diseaseEur Respir J19981247998049817148
   PubMed Web of Science ®Google Scholar
• DellacàRLPompilioPPWalkerPPDuffyNPedottiACalverleyPMEffect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPDEur Respir J20093361329133719164347
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMSeemugalTAThe role of bronchodilator treatment in the prevention of exacerbations of COPDEur Respir J20124061545155422835613
   PubMed Web of Science ®Google Scholar
• SlatonRMCruthirdsDLIndacaterol (Arcapta Neohaler) for chronic obstructive pulmonary diseaseP T2012372869822605898
   PubMedGoogle Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev201264345050422611179
   PubMed Web of Science ®Google Scholar
• YorganciogluAIndacaterol in chronic obstructive pulmonary disease: an update for cliniciansTher Adv Chronic Dis201231253623251766
   PubMedGoogle Scholar
• JonesPWBarnesNVogelmeierCLawrenceDKramerBEfficacy of indacaterol in the treatment of patients with COPDPrim Care Respir J201120438038821785813
   PubMedGoogle Scholar
• CazzolaMMateraMGLötvallJUltra-long acting β2 agonists in development for asthma and chronic obstructive pulmonary diseaseExpert Opin Investig Drugs2005147775783
   PubMed Web of Science ®Google Scholar
• MagnussenHVerkindreCJackDIndacaterol once-daily is equally effective dosed in the evening or morning in COPDRespir Med2010104121869187620850959
   PubMed Web of Science ®Google Scholar
• CalverleyPMLeeATowseLvan NoordJWitekTJKelsenSEffect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary diseaseThorax2003581085586014514937
   PubMed Web of Science ®Google Scholar
• ToyELBaulieuNUMcHaleJLTreatment of COPD: relationship between daily dosing frequency, adherence, resource use, and costsRespir Med2011105343544120880687
   PubMed Web of Science ®Google Scholar
• BeehKMBeierJThe short, the long, and the “ultra-long”: why duration of bronchodilator action matters in chronic obstructive pulmonary diseaseAdv Ther201027315015920411368
   PubMed Web of Science ®Google Scholar
• RennardSBantjeTCentanniSA dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparisonRespir Med200810271033104418479895
   PubMed Web of Science ®Google Scholar
• BarnesPJPocockSJMagnussenHIntegrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless designPulm Pharmacol Ther201023316517120080201
   PubMed Web of Science ®Google Scholar
• RenardDLoobyMKramerBLawrenceDMorrisDStanskiDRCharacterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approachesRespir Res2011125421518459
   PubMed Web of Science ®Google Scholar
• ChapmanKRRennardSIDograAOwenRLassenCKramerBLong-term safety and efficacy of indacaterol, a novel long-acting β2 agonist in subjects with COPD: a randomized, placebo-controlled studyChest20111401687521349928
   PubMed Web of Science ®Google Scholar
• KerwinEMGotfriedMHLawrenceDLassenCKramerBEfficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥ 40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studyClin Ther201133121974198422177371
   PubMed Web of Science ®Google Scholar
• GotfriedMHKerwinEMLawrenceDLassenCKramerBEfficacy of indacaterol 75 μg once daily on dyspnea and health status: results of two double-blind, placebo-controlled 12 week studiesCOPD20129662963623020650
   PubMedGoogle Scholar
• ChowdhuryBASeymourSMMicheleTMDurmowiczAGLiuDRosebraughCJThe risks and benefits of indacaterol – the FDA’s reviewN Engl J Med2011365242247224922168640
   PubMed Web of Science ®Google Scholar
• JonesPWDonohueJFNedelmanJPascoeSPinaultGLassenCCorrelating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespir Res20111216122206353
   PubMed Web of Science ®Google Scholar
• MahlerDAWeinbergDHWellsCKFeinsteinARThe measurements of dyspnea* Contents, interobserver agreement, and physiologic correlates of two new clinical indexesChest1984857517586723384
   PubMed Web of Science ®Google Scholar
• JonesPWQuality of life measurements for patients with diseases of the airwaysThorax1992466766821835178
   PubMed Web of Science ®Google Scholar
• DecramerMDahlRKornmannOKornSLawrenceDMcBryanDEffects of long-acting bronchodilators in COPD patients according to COPD severity and ICS useRespir Med2013107222323223219347
   PubMed Web of Science ®Google Scholar
• CazzolaMSegretiAStirpeEEffect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterolRespir Med2012107110711123083839
   PubMed Web of Science ®Google Scholar
• WorthHChungKFFelserJMHuHRueeggPCardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPDRespir Med2011105457157921227674
   PubMed Web of Science ®Google Scholar
• DonohueJFSinghDKornmannOLawrenceDLassenCKramerBSafety of indacaterol in the treatment of patients with COPDInt J Chron Obstruct Pulmon Dis2011647749222003293
   PubMed Web of Science ®Google Scholar
• BauwensONinaneVVan de MaeleB24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterolCurr Med Res Opin200925246347019192991
   PubMed Web of Science ®Google Scholar
• BeierJBeehKMBrookmanLPeacheyGHmissiAPascoeSBronchodilator effects of indacaterol and formoterol in patients with COPDPulm Pharmacol Ther200922649249619465142
   PubMed Web of Science ®Google Scholar
• DahlRChungKFBuhlREfficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
   PubMed Web of Science ®Google Scholar
• KornSKerwinEAtisSIndacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week studyRespir Med2011510571972621367594
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLötvallJOnce-daily bronchodilators for chronic obstructive pulmonary disease. Indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• VogelmeierCRamos-BarbonDJackDIndacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropiumRespir Res20101113520920365
   PubMed Web of Science ®Google Scholar
• BuhlRDunnLJDisdierCBlinded 12-week comparison of once-daily indacaterol and tiotropium in COPDEur Respir J201138479780321622587
   PubMed Web of Science ®Google Scholar
• ChapmanKRFogartyCMPeckittCDelivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPDInt J Chron Obstruct Pulmon Dis2011635336321760722
   PubMed Web of Science ®Google Scholar
• BeehKMBeierJDonohueJFClinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropiumRespir Res2012135222726538
   PubMed Web of Science ®Google Scholar
• RodrigoGJNeffenHComparison of indacaterol with tiotropium or twice-daily long-acting beta-agonists for stable COPD: a systematic reviewChest201214251104111022383666
   PubMed Web of Science ®Google Scholar
• CopeSCapkun-NiggliGGaleREfficacy of once-daily indacaterol relative to alternative bronchodilators value in COPD patients: a patient-level mixed treatment comparisonValue Health201215352453322583463
   PubMed Web of Science ®Google Scholar
• CopeSZhangJWilliamsJJansenJPEfficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysisBMC Pulm Med2012122922732017
   PubMed Web of Science ®Google Scholar
• BalintBWatzHAmosCOwenRHigginsMKramerBOnset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasoneInt J Chron Obstruct Pulmon Dis2010531131820856830
   PubMedGoogle Scholar
• CopeSCapkun-NiggliGGaleRJardimJRJansenJPComparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysisInt J Chron Obstruct Pulmon Dis2011632934421697997
   PubMed Web of Science ®Google Scholar
• CopeSKraemerMZhangJCapkun-NiggliGJansenJPEfficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysisInt J Chronic Obstruct Pulmon Dis20127415420
   Web of Science ®Google Scholar
• CorradoARossiAHow far is real life from COPD therapy guidelines. An Italian Observational StudyRespir Med2012106798999722483189
   PubMed Web of Science ®Google Scholar
• DecramerMRossiALawrenceDMcBryanDIndacaterol therapy in patients with COPD not receiving other maintenance treatmentRespir Med2012106121706171423031496
   PubMed Web of Science ®Google Scholar
• TroostersTCelliBLystigTTiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trialEur Respir J2010361657320185426
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBKestenSLystigTMehraSTashkinDPEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trialLancet200937496961171117819716598
   PubMed Web of Science ®Google Scholar
• PelkonenMNotkolaILNissinenATukiainenHKostelaHThirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural menChest200613041129113717035447
   PubMed Web of Science ®Google Scholar
• van DurmeYMVerhammeKMStijnenTPrevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam studyChest2009135236837719201711
   PubMed Web of Science ®Google Scholar
• TantucciCModinaDLung function decline in COPDInt J Chron Obstruc Pulmon Dis201279599
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Update 2010. Available from: http://www.goldcopd.com
   Google Scholar
• [No authors listed]In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study GroupChest19941055141114198181328
   PubMed Web of Science ®Google Scholar
• BuhlRBanerjiDProfile of glycopyrronium for once-daily treatment of moderate-to-severe COPDInt J Chron Obstruct Pulmon Dis2012772974123118536
   PubMed Web of Science ®Google Scholar
• Van de MaeleBFabbriLMMartinCHortonRDolkerMOverendTCardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patientsCOPD20107641842721166630
   PubMedGoogle Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med2013115160
   PubMed Web of Science ®Google Scholar
• O’DonnellDELavenezianaPOraJWebbKALamYAOfirDEvaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPDThorax200964321622319052054
   PubMed Web of Science ®Google Scholar
• O’DonnellDEVoducNFitzpatrickMWebbKAEffect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary diseaseEur Respir J2004241869415293609
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlϋgeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
   PubMed Web of Science ®Google Scholar
• RossiACentanniSCerveriIAcute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropiumRespir Med20121061849022035851
   PubMed Web of Science ®Google Scholar
• BeehKMWagnerFKhindriSDrollmannAFEffect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPDCOPD20118534021793716
   PubMedGoogle Scholar
• O’DonnellDECasaburiRVinckenWINABLE 1 study groupEffect of indacaterol on exercise endurance and lung hyperinflation in COPDRespir Med201110571030103621498063
   PubMed Web of Science ®Google Scholar
• HatajiONaitoMItoKWatanabeFGabazzaECTaguchiOIndacaterol improves daily physical activity in patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis201381523293514
   PubMed Web of Science ®Google Scholar
• ChangYHChenRCWahlqvistMLLeeMSFrequent shopping by men and women increases survival in the older Taiwanese populationJ Epidemiol Commun Health2012667e20
   Web of Science ®Google Scholar
• RussellRAnzuetoAWeismanIOptimizing management of chronic obstructive pulmonary disease in the upcoming decadeInt J Chron Obstruct Pulmon Dis20116476121311693
   PubMed Web of Science ®Google Scholar